Testing the divergent pathway hypothesis for melanoma: recent findings and future challenges

References

• Coory M, Baade P, Aitken J, Smithers M, McLeod GR, Ring I. Trends for in situ and invasive melanoma in Queensland, Australia, 1982–2002. Cancer Causes Control17(1), 21–27 (2006).
   PubMed Web of Science ®Google Scholar
• de Vries E, Coebergh JW. Melanoma incidence has risen in Europe. Br. Med. J.331, 698–699 (2005).
   PubMedGoogle Scholar
• Lens MB, Dawes M. Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma. Br. J. Dermatol.150(2), 179–185 (2004).
   PubMed Web of Science ®Google Scholar
• Jemal A, Devesa SS, Fears TR, Hartge P, Tucker MA. Recent trends in cutaneous melanoma incidence among whites in the United States. J. Natl Cancer Inst.93 678–683 (2001).
   PubMed Web of Science ®Google Scholar
• de Vries E, Bray FI, Coebergh JW, Parkin DM. Changing epidemiology of malignant cutaneous melanoma in Europe 1953–1997: rising trends in incidence and mortality but recent stabilizations in western Europe and decreases in Scandinavia. Int. J. Cancer107(1), 119–126 (2003).
   PubMed Web of Science ®Google Scholar
• Geller AC, Swetter SM, Brooks K, Demierre MF, Yaroch AL. Screening, early detection, and trends for melanoma: current status (2000–2006) and future directions. J. Am. Acad. Dermatol.57(4), 555–572 (2007).
   PubMedGoogle Scholar
• Armstrong BK, Kricker A. How much melanoma is caused by sun exposure? Melanoma Res.3, 395–401 (1993).
   PubMed Web of Science ®Google Scholar
• Jelfs PL, Giles G, Shugg D et al. Cutaneous malignant melanoma in Australia, 1989. Med. J. Aust.161, 182–187 (1994).
   PubMedGoogle Scholar
• Bulliard J-L. Site-specific risk of cutaneous malignant melanoma and pattern of sun exposure in New Zealand. Int. J. Cancer85, 627–632 (2000).
   PubMed Web of Science ®Google Scholar
• Lee JA. Declining effect of latitude on melanoma mortality rates in the United States. A preliminary study. Am. J. Epidemiol.146(5), 413–417 (1997).
   PubMed Web of Science ®Google Scholar
• Whiteman DC, Whiteman CA, Green AC. Childhood sun exposure as a risk factor for melanoma: a systematic review of epidemiologic studies. Cancer Causes Control12, 69–82 (2001).
   PubMed Web of Science ®Google Scholar
• Beral V, Robinson N. The relationship of malignant melanoma, basal and squamous skin cancers to indoor and outdoor work. Br. J. Cancer44, 886–891 (1981).
   PubMed Web of Science ®Google Scholar
• Vagero D, Ringback G, Kiviranta H. Melanoma and other tumours of the skin among office, other indoor workers and outdoor workers in Sweden 1961–1979. Br. J. Cancer53, 507–512 (1986).
   PubMed Web of Science ®Google Scholar
• Green A, MacLennan R, Youl P, Martin N. Site distribution of cutaneous melanoma in Queensland. Int. J. Cancer53, 232–236 (1993).
   PubMed Web of Science ®Google Scholar
• Elwood JM, Gallagher RP. Body site distribution of cutaneous malignant melanoma in relationship to patterns of sun exposure. Int. J. Cancer78, 276–280 (1998).
   PubMed Web of Science ®Google Scholar
• Whiteman DC, Watt P, Purdie DM, Hughes MC, Hayward NK, Green AC. Melanocytic nevi, solar keratoses, and divergent pathways to cutaneous melanoma. J. Natl Cancer Inst.95(11), 806–812 (2003).
   PubMedGoogle Scholar
• Lachiewicz AM, Berwick M, Wiggins CL, Thomas NE. Epidemiologic support for melanoma heterogeneity using the surveillance, epidemiology, and end results program. J. Invest. Dermatol.128(5), 1340–1342 (2008).
   PubMedGoogle Scholar
• Anderson WF, Pfeiffer RM, Tucker MA, Rosenberg PS. Divergent cancer pathways for early-onset and late-onset cutaneous malignant melanoma. Cancer115(18), 4176–4185 (2009).
   PubMed Web of Science ®Google Scholar
• Whiteman DC, Stickley M, Watt P, Hughes MC, Davis MB, Green AC. Anatomic site, sun exposure, and risk of cutaneous melanoma. J. Clin. Oncol.24(19), 3172–3177 (2006).
   PubMed Web of Science ®Google Scholar
• Carli P, Massi D, Santucci M, Biggeri A, Giannotti B. Cutaneous melanoma histologically associated with a nevus and melanoma de novo have a different profile of risk: results from a case–control study. J. Am. Acad. Dermatol.40(4), 549–557 (1999).
   PubMedGoogle Scholar
• Bevona C, Goggins W, Quinn T, Fullerton J, Tsao H. Cutaneous melanomas associated with nevi. Arch. Dermatol.139(12), 1620–1624 (2003).
   PubMedGoogle Scholar
• Purdue MP, From L, Armstrong BK et al. Etiologic and other factors predicting nevus-associated cutaneous malignant melanoma. Cancer Epidemiol. Biomarkers Prev.14(8), 2015–2022 (2005).
   PubMed Web of Science ®Google Scholar
• Lee EY, Williamson R, Watt P, Hughes MC, Green AC, Whiteman DC. Sun exposure and host phenotype as predictors of cutaneous melanoma associated with neval remnants or dermal elastosis. Int. J. Cancer119(3), 636–642 (2006).
   PubMed Web of Science ®Google Scholar
• Pharoah PD. Shedding light on skin cancer. Nat. Genet.40(7), 817–818 (2008).
   PubMedGoogle Scholar
• Brown KM, Macgregor S, Montgomery GW et al. Common sequence variants on 20q11.22 confer melanoma susceptibility. Nat. Genet.40(7), 838–840 (2008).
   PubMed Web of Science ®Google Scholar
• Hocker T, Tsao H. Ultraviolet radiation and melanoma: a systematic review and analysis of reported sequence variants. Hum. Mutat.28(6), 578–588 (2007).
   PubMed Web of Science ®Google Scholar
• Purdue MP, From L, Kahn HJ et al. Etiologic factors associated with p53 immunostaining in cutaneous malignant melanoma. Int. J. Cancer117(3), 486–493 (2005).
   PubMed Web of Science ®Google Scholar
• Whiteman DC, Green A, Parson PG. p53 expression and risk factors for cutaneous melanoma: a case–control study. Int. J. Cancer77 843–848 (1998).
   PubMed Web of Science ®Google Scholar
• Maldonado JL, Fridlyand J, Patel H et al. Determinants of BRAF mutations in primary melanomas. J. Natl Cancer Inst.95(24), 1878–1890 (2003).
   PubMed Web of Science ®Google Scholar
• Thomas NE. BRAF somatic mutations in malignant melanoma and melanocytic naevi. Melanoma Res.16(2), 97–103 (2006).
   PubMedGoogle Scholar
• Lang J, MacKie RM. Prevalence of exon 15 BRAF mutations in primary melanoma of the superficial spreading, nodular, acral, and lentigo maligna subtypes. J. Invest. Dermatol.125(3), 575–579 (2005).
   PubMedGoogle Scholar
• Thomas NE, Edmiston SN, Alexander A et al. Number of nevi and early-life ambient UV exposure are associated with BRAF-mutant melanoma. Cancer Epidemiol. Biomarkers Prev.16(5), 991–997 (2007).
   PubMed Web of Science ®Google Scholar
• Liu W, Kelly JW, Trivett M et al. Distinct clinical and pathological features are associated with the BRAF(T1799A(V600E)) mutation in primary melanoma. J. Invest. Dermatol.127(4), 900–905 (2007).
   PubMedGoogle Scholar
• Poynter JN, Elder JT, Fullen DR et al.BRAF and NRAS mutations in melanoma and melanocytic nevi. Melanoma Res.16(4), 267–273 (2006).
   PubMed Web of Science ®Google Scholar
• Edlundh-Rose E, Egyhazi S, Omholt K et al.NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing. Melanoma Res.16(6), 471–478 (2006).
   PubMed Web of Science ®Google Scholar
• Bauer J, Curtin JA, Pinkel D, Bastian BC. Congenital melanocytic nevi frequently harbor NRAS mutations but no BRAF mutations. J. Invest. Dermatol.127(1), 179–182 (2007).
   PubMed Web of Science ®Google Scholar
• Garrido MC, Bastian BC. KIT as a therapeutic target in melanoma. J. Invest. Dermatol.130(1), 20–27 (2010).
   PubMedGoogle Scholar
• Pleasance ED, Cheetham RK, Stephens PJ et al. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature463(7278), 191–196 (2010).
   PubMed Web of Science ®Google Scholar